[ad_1]
ILLUSTRATION
Source: Reuters The | Editor: H.H. Kurniawan
KONTAN.CO.ID – ZURICH. Pfizer sets a goal: It can produce 10-20 million doses of vaccines for the new coronavirus that they developed with BioNtech in late 2020 for emergency use.
Pfizer from the United States (USA) and BioNtech from Germany, which are developing four candidate vaccines, have administered the first dose to humans in Germany and hope to begin trials in the US soon. USA While they wait for regulatory approval.
Pfizer, BioNtech and many other companies and scientists are competing to develop vaccines for the coronavirus. AstraZeneca, who joined Oxford University on a vaccine project, has also evaluated volunteers.
Also read: See Sinovac’s journey to develop the coronavirus vaccine
Delivering millions of doses in just a few months, as Pfizer had hoped, would set an unprecedented rate for new vaccines and would require swift regulatory action even for emergency use.
“Of course, we have to look and wait to see how the efficacy and safety of vaccines are showing, hopefully in the coming months,” Nanette Cocero, global director of Pfizer Vaccines, said in a video conference by the International Federation. of Pharmaceutical Manufacturers and Associations (IFPMA) on Thursday (4/30).
-> Featured videos
->
->
CROWN VIRUSES
->
